REPL
Q4 2026 EPS Estimate
$-0.75
Nov 5, 2026 · Reports before open
Revenue Estimate
$1M
FY2030E EPS$0.05
FY2031E EPS$1.02

Analyst Sentiment

Wall St. Consensus
Buy
15 analysts·Moderate coverage
67
Score
11 Buy (73%)3 Hold (20%)1 Sell (7%)
Rating Breakdown
Strong Buy
00%
Buy
1173%
Hold
320%
Sell
17%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$17.00
+13.8%
Consensus
$19.00
+27.2%
Bull
$20.00
+33.9%
12-Month Target Range15 analysts
$17.00$19.00$20.00
Current $14.94Consensus
Current Price
$14.94
Upside to Consensus
$4.06

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+913.89%
EPS
FY2028
Rev+295.49%
EPS
FY2029
Rev+40.56%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2027EFY2028EFY2029EFY2030EFY2031E
Revenue Avg$44M$175M$247M$389M$547M
Low$21M$130M$103M$125M$176M
High$77M$241M$345M$647M$909M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-302M$-190M$-116M$5M$94M
Low$-368M$-203M$-290M$573,729$11M
High$-183M$-177M$58M$9M$175M
EPS Avg$-2.86$-2.01$-1.04$0.05$1.02
Low$-3.96$-2.19$-3.12$0.01$0.12
High$-1.98$-1.91$0.63$0.10$1.89
Analysts (Rev / EPS)5 / 55 / 34 / 42 / 11 / 2
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$1M$9M$29M$43M$51M$44M$52M$71M
Low$462,908$4M$13M$20M$24M$20M$24M$33M
High$2M$14M$47M$70M$84M$73M$85M$116M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-76M$-77M$-69M$-47M$-48M$-46M$-41M$-24M
Low$-103M$-102M$-127M$-86M$-88M$-85M$-76M$-44M
High$-61M$-63M$-21M$-14M$-14M$-14M$-12M$-7M
EPS Avg$-0.79$-0.80$-0.71$-0.48$-0.49$-0.47$-0.43$-0.25
Low$-1.07$-1.05$-1.31$-0.89$-0.91$-0.87$-0.79$-0.46
High$-0.63$-0.65$-0.21$-0.15$-0.15$-0.14$-0.13$-0.08
Analysts (Rev / EPS)5 / 25 / 24 / 14 / 14 / 14 / 13 / 13 / 1

Earnings Surprises

Recent Analyst Actions

Aug 7, 2026BMO Capital
Replimune price target raised to $20 from $16 at BMO Capital
Target:$20.00
+55.5%from $12.86
Aug 7, 2026Wedbush
Wedbush Upgrades Replimune Group (REPL) to Outperform
Target:$19.00
+47.7%from $12.86
Aug 4, 2026Leerink Partners
Leerink Upgrades Replimune Group (REPL) to Outperform
Target:$17.00
+42.7%from $11.91
Jul 31, 2026Wedbush
Wedbush Upgrades Replimune Group (REPL) to Outperform
Target:$12.00
+121.8%from $5.41
Jun 30, 2026Wedbush
Replimune price target raised to $9 from $6 at Wedbush
Target:$9.00
-19.6%from $11.20
Jun 30, 2026BMO Capital
Replimune upgraded to Outperform from Market Perform at BMO Capital
Target:$16.00
+42.9%from $11.20
Feb 5, 2026Piper Sandler
Replimune price target raised to $14 from $13 at Piper Sandler
Target:$14.00
+100.0%from $7.00
Nov 3, 2025BMO Capital
Replimune upgraded to Market Perform from Underperform at BMO Capital
Target:$11.00
+13.1%from $9.73
Oct 27, 2025H.C. Wainwright
Replimune upgraded to Buy from Neutral at H.C. Wainwright
Target:$12.00
+36.4%from $8.80
Oct 20, 2025Wedbush
Wedbush upgrades Replimune to Outperform amid second BLA review
Target:$18.00
+96.7%from $9.15
Jan 22, 2025BMO Capital
Replimune price target raised to $27 from $18 at BMO Capital
Target:$27.00
+106.3%from $13.09
Dec 3, 2024Jefferies
Replimune Group (REPL) PT Raised to $19 at Jefferies
Target:$19.00
+31.2%from $14.48
Jun 7, 2024H.C. Wainwright
Replimune Group price target raised to $17 from $12 at H.C. Wainwright
Target:$17.00
+139.1%from $7.11
Jun 4, 2024Barclays
Barclays Reiterates Overweight Rating on Replimune Group (REPL)
Target:$13.00
+142.1%from $5.37
May 17, 2024BMO Capital
BMO Capital Reiterates Outperform Rating on Replimune Group (REPL)
Target:$14.00
+104.4%from $6.85
Dec 12, 2022BMO Capital
BMO Capital Maintains Outperform on Replimune Group, Raises Price Target to $70
Target:$70.00
+180.0%from $25.00
Dec 7, 2022Leerink Partners
SVB Leerink Maintains Outperform on Replimune Group, Raises Price Target to $34
Target:$34.00
+47.2%from $23.09
Oct 3, 2022Leerink Partners
SVB Leerink Maintains Outperform on Replimune Group, Lowers Price Target to $30
Target:$30.00
+73.7%from $17.27
Aug 17, 2022Piper Sandler
Piper Sandler Maintains Overweight on Replimune Group, Lowers Price Target to $43
Target:$43.00
+108.5%from $20.62
Aug 5, 2022Leerink Partners
SVB Leerink Maintains Outperform on Replimune Group, Lowers Price Target to $37
Target:$37.00
+81.6%from $20.37
May 20, 2022Leerink Partners
SVB Leerink Maintains Outperform on Replimune Group, Lowers Price Target to $48
Target:$48.00
+233.8%from $14.38
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.